Filgotinib for Treatment-Resistant Rheumatoid Arthritis, Intensive vs Standard Glucose Management in Acute Stroke, Neuroimaging Finding in US Cuban Government Personnel, and more
Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the July 23, 2019 issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - July 23, 2019 Category: General Medicine Authors: JAMA Network Source Type: podcasts
Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - July 12, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts
John Tesser, MD, FACP, FACR - Overcoming Challenges in the Management of Refractory Rheumatoid Arthritis: Expert Insight on the Clinical Potential of Novel Therapeutic Options
Go online to PeerView.com/XQR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses the role of novel therapeutic options in overcoming challenges associated with the management of patients with refractory rheumatoid arthritis. Upon completion of this activity, participants should be better able to: Recognize challenges associated with the management of refractory rheumatoid arthritis, Identify novel therapeutic options for rheumatoid arthritis in the context of mechanism of action, efficacy, and safety, Employ current ev...
Source: PeerView CME/CE Audio Podcast - Immunology - May 13, 2019 Category: Allergy & Immunology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
Leonard H. Calabrese, DO - Rheumatology, Immunology, and Immuno-Oncology Intersect: Navigating the Complexities of Immune Checkpoint Inhibition, Autoimmunity, and Immune-Related Adverse Events: How Can Rheumatologists Help Minimize the Risks and Maximize the Benefits of Cancer Immunotherapies?
Go online to PeerView.com/GQF860 to view the entire program with slides.In this video panel discussion, Leonard H. Calabrese, DO, and Evan J. Lipson, MD, engage in an interdisciplinary discussion of why it is important for rheumatologists to have a good grasp of immuno-oncology (IO) in general and of the unique immune-related adverse events (irAEs) associated with cancer immunotherapies in particular. They explore the new class of immune checkpoint inhibitors, how they work, in which cancer types they’re used, why and how irAEs develop, and which rheumatic irAEs can occur as part of the broad spectrum of potential irAEs....
Source: PeerView CME/CE Audio Podcast - Immunology - April 12, 2019 Category: Allergy & Immunology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 5, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate
On February 25, 2019 FDA alerted the public that a safety clinical trial found an increased risk of blood clots in the lungs and death when a 10 mg twice daily dose of tofacitinib (brand names Xeljanz, Xeljanz XR) was used in patients with rheumatoid arthritis (or RA). (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 5, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
"Absorbing News" -- The Discovery Files
Engineers at the University of California, San Diego, have developed "nanosponges" that can safely absorb and neutralize a variety of proteins that play a role in the progression of rheumatoid arthritis. Injections of these nanosponges effectively treated severe rheumatoid arthritis in two mouse models, and administering the nanosponges early on prevented the disease from developing. (Source: The Discovery Files)
Source: The Discovery Files - February 7, 2019 Category: Science Authors: National Science Foundation Source Type: podcasts
Randy Q. Cron, MD, PhD - Systemic Juvenile Idiopathic Arthritis: A Closer Look at the Burden on Patients and Caregivers From Diagnosis to Treatment
Systemic Juvenile Idiopathic Arthritis: A Closer Look at the Burden on Patients and Caregivers From Diagnosis to Treatment (Source: PeerView CME/CE Audio Podcast - Primary Care)
Source: PeerView CME/CE Audio Podcast - Primary Care - January 16, 2019 Category: Primary Care Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
